ArticleBMC medicine2025
Sodium-glucose transport protein 2 inhibitor use in diabetes and its association with tuberculosis incidence.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose cotransporter 2 inhibitors (SGLT2i) are increasingly prescribed in diabetes mellitus (DM) patients, yet their impact on tuberculosis (TB) incidence remains unclear. This study analyzed TB risk in DM patients with and without SGLT2i use.
methodsWe conducted a retrospective cohort study using data from the Taiwan National Health Insurance Research Database between 2017 to 2020. DM patients treated with or without SGLT2i were identified, and propensity score (PS) matching was performed to balance baseline characteristics, including age, sex, comorbidities, and Diabetes Complications Severity Index (DCSI) between these two groups. TB incidence was assessed until December 31, 2021, and compared between groups. To consider death as a competing risk, a Cox regression model with the Fine and Gray approach was used to estimate the incidence of TB. Additionally, sensitivity analyses were conducted by excluding patients with concomitant antidiabetic medications and by redefining the exposure period based on the timing of SGLT2i initiation.
resultsAfter PS matching, 76,159 SGLT2i users and 152,318 non-users were included. The majority of enrolled patients were aged over 50 years (63.96%), with males predominant (61.92%). Over an average follow-up of 3.08 years, TB incidence was lower in SGLT2i users than in non-users (0.10% vs. 0.17%, SMD = 0.0192). The time to TB diagnosis was longer in SGLT2i users compared to non-users (2.56 ± 1.13 vs. 2.27 ± 0.02, SMD = -0.2853). Cox regression showed a reduced TB risk in SGLT2i users, with an adjusted hazard ratio of 0.43 (95% CI: 0.33-0.56). The protective effect persisted across age, gender and concomitant use of other antidiabetic drugs. A dose-response relationship was observed, where patients receiving higher cumulated defined daily doses of SGLT2i exhibited progressively lower TB risk. Finally, sensitivity analyses reinforced the robustness of the findings and suggested a temporal association between SGLT2i exposure and a reduced risk of TB occurrence.
conclusionsThis study provides novel evidence that SGLT2i use is associated with a lower TB risk in DM patients, suggesting a potential host-directed therapeutic role warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.